Remote Electrical Neuromodulation

SAN DIEGO — A wearable remote electrical neuromodulation device provided consistent efficacy and clinically meaningful benefit to those with migraine, according to a poster presentation at the American Headache Society Annual Scientific Meeting.

CVRx Inc. announced the FDA approved its revised instructions for use for its baroreflex activation therapy device incorporating clinical data from the BeAT-HF randomized clinical trial.

AUSTIN, Texas — The use of remote electrical neuromodulation in adolescents with acute migraine was safe and efficacious as a nonpharmacological treatment option, according to a poster presented here.

CVRx Inc. announced the launch of its next-generation programmer for its implantable pulse neuromodulation generator to treat HF symptoms.

The FDA has expanded the approval of a remote electrical neuromodulation device to treat episodic and chronic migraine in children aged 12 years and older, according to a press release issued by the manufacturer.

Many neurostimulation methods have been developed for the prevention and treatment of migraine and while some appear to be useful, the quality of available evidence for most is poor, according to a study published in The Journal of Headache and Pain.

The FDA has expanded the approval for Nerivio, a wearable remote electrical neuromodulation device controlled by a smartphone app, to treat chronic migraine in adults aged 18 years and older.